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Purpose: Hybrid therapy with catheter ablation of the cavo-tricuspid isthmus (CTI) 
and continuation of anti-arrhythmic drugs (AAD), or electrical cardioversion with 
AADs might be alternative treatments for patients with persistent atrial fibrillation 
(AF). The goal of study was to assess the long term success rate of hybrid therapy 
for persistent AF compared to antiarrhythmic medication therapy after electrical 
cardioversion and identify the independent risk factors associated with recurrence 
after hybrid therapy. Materials and Methods: A total of 32 patients with persistent 
AF who developed atrial flutter after the administration of a class Ic or III anti-ar-
rhythmic drug were enrolled. This group was compared with a group (33 patients) 
who underwent cardioversion and received direct current cardioversion with AADs. 
Baseline data were collected, and electrocardiogram and symptom driven Holter 
monitoring were performed every 2-4 months. Results: There was no significant 
difference in the baseline characteristics between the groups. The 12 month atrial 
arrhythmia free survival was better in the hybrid group, 49.0% vs. 33.1%, p=0.048. 
However, during a mean 55.7+/- 43.0 months of follow up, the improved survival 
rate regressed (p=0.25). A larger left atrium size was an independent risk factor for 
the recurrence of AF after adjusting for confounding factors. Conclusion: Despite 
favorable outcome during 12 month, the CTI block with AADs showed outcomes 
similar to AAD therapy after electrical cardioversion over a 12 month follow up pe-
riod. Minimal substrate modification with AADs might be an alternative treatment 
for persistent AF with minimal atrial remodeling.
Key Words:    Atrial fibrillation, atrial flutter, cavo-tricuspid isthmus, antiarrhyth-
mic drug
INTRODUCTION
Catheter ablation is considered standard therapy by current treatment guidelines1 
for patients with symptomatic paroxysmal atrial fibrillation (AF) who do not re-
spond to single antiarrhythmic drug therapy (AAD). However, the effectiveness of 
catheter ablation is low in patients with persistent AF despite prolongation of the 
complex procedure.2-4 Therefore, the mainstay of therapy for these patients has CTI Block in Persistent AF
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 2012 77
identified 32 patients who developed atrial flutter after anti-
arrhythmic drug therapy for chronic persistent AF without 
evidence of pre-drug atrial flutter (hybrid group). The clini-
cal outcomes and echocardiographic data from this group 
were compared to those of 33 persistent AF patients that 
underwent successful electrical cardioversion with antiar-
rhythmics during the same period electrocardioversion 
group (EC group).
Demographic, clinical and procedural variables were col-
lected retrospectively by review of the medical records. All 
patients underwent non-invasive cardiac examination in-
cluding M-mode and two dimensional echocardiography 
with color Doppler flow analysis. Valvular heart disease was 
defined as existence of moderate to severe regurgitation or 
stenosis of valve in echocardiography. Left atrial enlarge-
ment was defined as a left atrial anterior-posterior diameter 
more than 44 mm.
This study received approval from the institutional ethics 
committee, and the procedures followed were in accordance 
with the institutional guideline.
 
Electrophysiological studies and catheter ablation  
of atrial flutter
All patients in the hybrid group received electrophysiological 
studies and radiofrequency ablation after informed consent 
was obtained. Antiarrhythmics were continued. Three multi-
polar electrode catheters were inserted percutaneously into 
the left femoral vein. Two quadripolar catheters (2-5-2 mm 
spacing, DAIG, St Jude Medical Inc., St. Paul, MN, USA) 
were positioned at the his bundle and right atrium. A decap-
olar catheter (2-5-2 mm spacing, DAIG, St Jude Medical 
Inc., St. Paul, MN, USA) was positioned in the coronary si-
nus via the left subclavian vein. Activation sequence of atri-
al flutter or entrapment mapping was assessed by a 20-pole 
electrode halo catheter (2-10-2 mm spacing, Biosense-
Webster, Diamond Bar, CA, USA). The position of the 
catheters was checked in the 45° left anterior oblique view 
and the 30° right anterior oblique view. A deflectable 5 mm-
tipped quadripolar catheter or irrigation catheter was used 
as the ablation catheter. The electrophysiological definition 
of isthmus dependent atrial flutter was demonstrated by the 
standard criteria9 for entrainment mapping. A 500 kHz ra-
diofrequency (RF) ablation unit (Stockert, Biosense-web-
ster, Diamond Bar, CA, USA) was used for the ablation. RF 
ablation started at the ventricular side of inferolateral tricus-
pid annulus and the end point was bidirectional block of 
isthmic conduction. 
been long-term AAD even though persistent AF is poorly 
controlled by AAD therapy. Furthermore, in the latest 
guideline,1 longterm AAD therapy is indicated in patients 
who have troublesome symptoms related to paroxysmal AF 
or recurrent AF after cardioversion who can tolerate antiar-
rhythmic drugs and have a good chance of remaining in si-
nus rhythm over an extended period (e.g., young patients 
without organic heart disease or hypertension, a short dura-
tion of AF, and normal LA size). In some patients, AF 
evolves to typical atrial flutter after the initiation of anti-ar-
rhythmic drug therapy. Previously, catheter ablation of the 
inferior vena cava-tricuspid annulus isthmus along with 
continuation of anti-arrhythmic medication therapy (hybrid 
therapy) has been shown to be effective treatment for anti-
arrhythmic drug-induced atrial flutter.5-8 Although a high 
initial success rate establishing a stable sinus rhythm has 
been described in patients with hybrid therapy, post-abla-
tion atrial fibrillation can recur during follow-up, despite 
the continuation of anti-arrhythmic medication. Most pa-
tients have good immediate and intermediate outcomes with 
hybrid therapy in regard to their paroxysmal AF. Hybrid 
therapy may be effective in patients with conversion to typ-
ical atrial flutter occurring in 10 to 15% of patients with 
persistent AF who are undergoing antiarrhythmic medica-
tion. However, the long term clinical outcome of hybrid ther-
apy in patients with chronic persistent AF has not yet been 
evaluated and the risk factors associated with the recur-
rence of AF have not been identified. Furthermore, there is 
few data comparing hybrid therapy and drug therapy after 
electrical cardioversion.
Therefore, the goal of this study was to assess the long 
term success rate of hybrid therapy for persistent AF com-
pared to sole antiarrhythmic medication therapy after elec-
trical cardioversion and identify the independent risk fac-
tors associated with recurrence after hybrid therapy in 
patients with persistent AF.
MATERIALS AND METHODS
　
Patient population
Persistent AF was defined as AF lasting more than 7 days. 
It was considered to be highly likely if two electrocardio-
graphic studies, including 24 hour Holter monitoring, were 
without an episode of sinus rhythm. From January 1999 to 
December 2007, 250 patients underwent catheter ablation 
for atrial flutter at our institution. Among these patients, we Jin-Bae Kim, et al.
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gorical variables, respectively. The 95% confidence interval 
(CI) was determined on the basis of the normal distribution 
of variables. Kaplan-Meier estimates were used to deter-
mine overall survival and event-free survival for both groups. 
Comparison between the groups was performed using the 
log-rank test. Cox regression hazard analysis was used to 
identify independent correlates of long-term event-free sur-
vival. All analyses were performed using SPSS software 
version 11.5 (SPSS Inc., Chicago, IL, USA).
 
RESULTS
 
Clinical characteristics of patients 
The baseline characteristics of both groups of patients are 
listed in Table 1. When compared with the cardioversion 
group, the hybrid group included more patients with diabe-
tes (28.1% vs. 9.1%; p=0.018). However, there was no dif-
ference in age, gender, body mass index, or valvular heart 
disease. No significant difference was found with regard to 
the periprocedural medications such as antiarrhythmics, an-
giotensin converting enzyme inhibitors/angiotensin recep-
tor blockers, beta blockers and calcium channel blockers 
between the two groups. The pre-procedural echocardio-
graphic parameters showed that the left ventricular dimen-
sion and left ventricular systolic function were within nor-
mal range and there was no difference between the groups. 
The left atrial size, measured by the anterior-posterior dis-
tance in the parasternal long axis view, was not statistically 
different;  patients with more than 44 mm left atrial anteri-
or-posterior diameter were more common in the hybrid 
group, but the difference was not statistically significant 
(53.1% vs. 48.5%, p=0.68). 
Catheter ablation of atrial flutter and electrical 
cardioversion
Four patients (12.5%) in the hybrid group presented with 
atypical atrial flutter on the 12 lead ECG and showed clock-
wise atrial activation sequences. Atypical atrial flutter was 
treated with the catheter ablation procedure. It was cavo-tri-
cuspid isthmus (CTI) dependent and successfully ablated 
with CTI block; 28 patients (87.5%) had common atrial 
flutter and all atrial flutters were cavo-tricuspid isthmus de-
pendent as proven by entrapment mapping and terminated 
by CTI block. The mean cycle length of the atrial flutter on 
the electrophysiological studies was 325.8+/-127.6 ms. All 
patients achieved complete bidirectional isthmus block and 
Delivery of impulses was guided by impedance control. 
A bidirectional isthmus block was demonstrated by pacing 
technique which was performed at coronary sinus ostium 
and the low lateral right atrium. The line of block was re-
evaluated 30 min after the catheter ablation. 
Electrical cardioversion of persistent AF
Electrical cardioversion was performed after 4-6 weeks of 
anticoagulation with warfarin or when LA thrombi were 
not seen on the transesophageal echocardiography. R wave 
synchronized direct current (DC) shock with a monophasic 
or biphasic waveform was delivered during sedation in-
duced by intravenous pentothal sodium (1.5 mg/kg). One 
defibrillator pad, with a 10-cm diameter, was placed at the 
second intercostal space on the right side parasternally and 
the other was placed at a left-sided lateral position along the 
midaxillary line. The cardioversion procedure started with 
100 J (biphasic) or 200 J (monophasic), followed by 200 J 
and 300 J, until the restoration of sinus rhythm.
Data collection and follow-up
Demographic, clinical and procedural variables were col-
lected retrospectively by review of the medical records. All 
patients in both groups were instructed to continue the anti-
arrhythmic medications. Most patients received warfarin to 
maintain an International Normalized Ratio of 2.0-3.0 for at 
least one month after the ablation. In some patients who 
had no indications for systemic anticoagulation, warfarin 
was changed to aspirin 100 mg daily after 1-2 months of 
anticoagulation. All patients had regular follow-up with 
standard 12 lead electrocardiogram (ECG) in the out-patient 
clinic every 2-4 months or Holter monitoring if the patient 
was symptomatic. Patients with palpitations or symptoms 
suggestive of atrial fibrillation or atrial flutter underwent am-
bulatory 24-hour Holter monitoring. Recurrent atrial fibril-
lation was diagnosed when documented by ECG or Holter 
monitoring. Patients were instructed to obtain an ECG at 
the nearest hospital in cases where symptomatic palpitation 
developed. Patients were followed for a mean period of 
55.7+/-43.0 months (up to 7 years) after catheter ablation or 
electrical cardioversion. The follow-up end point was recur-
rence of atrial fibrillation or flutter.
Statistical analysis
Continuous variables are expressed as mean±SD, and cate-
gorical variables as percents. The unpaired Student t-test 
and χ2 analysis were used to compare continuous and cate-CTI Block in Persistent AF
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type of procedure (Hybrid or EC) was not a statistically sig-
nificant indicator of the long-term outcome. The preproce-
dural LA size was the only independent risk factor for the 
recurrence of atrial arrhythmia after adjusting for age, gen-
der, diabetes, hypertension, stroke and ejection fraction 
(odd ratio 2.5, CI of 95% 1.494-3.66, p=0.02) (Table 2).
DISCUSSION
In comparison with paroxysmal AF, persistent AF has a dif-
ferent underlying pathophysiological mechanism.10,11 There 
are definite triggers and drivers of paroxysmal AF that can-
not maintain long term fibrillatory activity. Paroxysmal AF 
is frequently triggered by ectopic beats from the muscular 
non-inducibility of atrial flutter, which was the end point of 
the catheter ablation. The procedure time, flouro time and 
RF time were: 87.3±42.6 min, 32.8±12.6 min, and 
1,034.7±698.2 sec, respectively. All patients in the EC 
group achieved a sinus rhythm after cardioversion without 
complication.
Clinical follow-up
The mean follow-up was 67+/-33 months and 101+/-38 
months in the hybrid group and EC group, respectively. 
During the follow-up period, recurrent atrial fibrillation or 
atrial tachycardia/flutter were developed in all patients. In 
the hybrid group, typical atrial flutter recurred in 2 patients, 
and atrial tachycardia or atypical atrial flutter developed in 
13 patients. Seventeen patients experienced atrial fibrilla-
tion. In the EC group, atrial fibrillation recurred in the greater 
part of patients, and atrial tachycardia or atypical atrial flut-
ter developed in 4 patients. Typical atrial flutter developed 
in three patients. By Kaplan-Meier estimates, the 12 month 
AF free-survival was better in the hybrid group (12 months 
event-free survival 49.0% for the hybrid group patients and 
33.1% for the EC group patients, p=0.048) (Fig. 1). How-
ever, during a mean of 55.7+/-43.0 months of follow up, 
this better survival rate regressed (5 year event-free survival 
24.0% for the hybrid group patients and 16.5% for EC group 
patients, p=0.28) (Fig. 2). On the multivariate analysis, the 
Table 1. Baseline Characteristics
Hybrid group (n=32) Electrical cardioversion group (n=33) p value
Age (yrs) 55.4±12 52.7±12 0.227
Gender (male/female) 27/5 29/4 0.683
AF duration (months)   64.7±54.0   42.0±38.2 0.082
BMI (kg/m
2)  25.2±3.5 25.7±3.7 0.731
Hypertension 10 (31.3%)   7 (21.2%) 0.357
Diabetes   9 (28.1%) 3 (9.1%) 0.018
Valvular heart disease 3 (9.4%)   4 (12.1%) 0.721
Stroke 3 (9.4%) 2 (6.1%) 0.616
LV EF 49.8±6.6 52.4±7.1 0.602
LA diameter (AP)  45.2±6.2 44.2±7.9 0.578
LA diameter >44 mm 17 (53.1%) 16 (48.5%) 0.708
AAD 0.253
    Class Ic 27 (84.4%) 24 (72.7%)
        (flecainide/propafenone) 24/3 20/4
    Class III   5 (15.6%)   9 (27.3%)
        (amiodarone/sotalol) 3/2 6/3
ACEI/ARB 3 (9.4%)   5 (15.2%) 0.479
Beta blocker 11 (34.4%) 12 (36.4%) 0.867
Statin   5 (15.6%) 2 (6.1%) 0.214
BMI, Body mass index; LV EF, left ventricular ejection fraction; AP, anteroposterior diameter; AAD, antiarrhythmic drug; ACEI, angioten-
sin converting enzyme inhibitor; ARB, angiotensin receptor blocker; AF, atrial fibrillation; LA, left atrium.
Table 2. Multivariate Analysis of Longterm Outcome
Variables Risk ratio p value
Age 1.02 0.068
Sex 0.84 0.284
Hypertension 0.98 0.791
Diabetes 0.85 0.435
Stroke 1.06 0.732
Treatment group* 1.03 0.937
Enlarged LA
† 1.53 0.027
*Hybrid group and electrical cardioversion group. 
†Anteroposterior diameter >44 mm.Jin-Bae Kim, et al.
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ablation studies in patients with chronic persistent AF.16 
Furthermore, a worldwide survey revealed that the success 
rate of AF ablation, including patients with paroxysmal and 
persistent AF, varied according to the volume of cases un-
dergoing the procedure per center, and that the major com-
plication rate was 5.9%, including early deaths.17 The re-
sults of this study and the evidence from previous studies7,8 
suggest that hybrid treatment is a reasonable approach for 
patients with atrial flutter that evolved from persistent AF.
In contrast to hybrid therapy, sole antiarrhythmic medica-
tion therapy after direct current (DC) cardioversion had a 
poorer outcome over the 12 months of follow up. Previously, 
the PAFAC trial reported a 65-67% rate of AF recurrence af-
ter DC cardioversion.18 In the trial, sotalol and quinidine were 
used as antiarrhythmic medications, and the clinical out-
come was comparable with the use of flecainide, propafe-
none or amiodarone in our present study. However, during a 
mean of 55.7+/-43.0 months of follow up, the benefit of hy-
brid therapy regressed and was not significant compared to 
single drug therapy (p=0.25). Reithmann, et al.19 reported 
that the presence of pre-ablation episodes of atrial fibrilla-
tion, in patients taking anti-arrhythmic medication, and a 
decreased left ventricular ejection fraction were significant 
and independent predictors of post-ablation atrial fibrilla-
tion. In our study, the only independent risk factor for re-
currence of AF was the pre-ablative LA size. The likely ex-
planation for this result is atrial electrical and structural 
remodeling. Electrical remodeling accompanied by struc-
tural remodeling acts as substrate, and more modification of 
the substrate is required to restore sinus rhythm.
Stabile, et al.20 reported that single drug therapy in pa-
tients with atrial flutter, after flecainide infusion, showed an 
80% AF recurrence rate over 12 months period, suggesting 
sleeve extending from the left atrium into the pulmonary 
veins (PV). Therefore, the target of treatment is the elimina-
tion of these triggers and drivers, such as PV isolation. How-
ever, in patients with persistent AF, the triggers and drivers 
are located at unusual sites, and the fibrillatory activity is 
independent. The remodeled atria act as substrate and can 
perpetuate fibrillatory waves and independently maintain 
chaotic electrical activity. Therefore, for restoration of sinus 
rhythm, more prolonged and highly sophisticated proce-
dures are required for the treatment of patients with chronic 
persistent AF, and the efficacy of catheter ablation is lower 
than in paroxysmal AF, with a significant increase in the as-
sociated risk of procedural complications.
Several alternative strategies have been considered for 
these patients. Hybrid therapy, a combined method of phar-
macological and non- pharmacological therapy, is one of 
the alternatives; it can be used for certain patients with atri-
al flutter that is transformed from atrial fibrillation after ini-
tiation of drug treatment. A previous study indicates that the 
incidence of drug-related atrial flutter is up to 12.8% among 
patients that had received classic anti-arrhythmic drug ther-
apy for atrial fibrillation.6,12 In these patients, hybrid therapy 
has a good outcome without significant complications. Dif-
ferent studies have documented 7% up to 42% AF recur-
rence rate during 12 month to 2 year follow up.13-15 Howev-
er, these studies included more paroxysmal patients than 
persistent and detected AF recurrence with symptom driven 
ECG recording. In contrast to previous studies, the present 
study included only patients with chronic persistent AF 
which continued overall 50 months, and showed a higher 
recurrence rate of AF by regular ECG follow up and symp-
tom-driven Holter monitoring. However, the 12 month AF 
free-survival rate was comparable to that of previous AF 
Fig. 1. Comparision of 12 month event free survival curves between hybrid 
and electrical cardioversion group patients. AF, atrial fibrillation.
Fig. 2. Comparision of long term event free survival curves between hybrid 
and electrical cardioversion group patients. AF, atrial fibrillation.
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ter caused by atrial fibrillation after anti-arrhythmic drug 
use could not be estimated. Although the general incidence 
of atrial flutter transformed from atrial fibrillation has been 
reported to be 10 to 20%, this data were collected, based on a 
Western study; there are no data on Asian populations. Even 
though standard 12 lead ECG was regularly performed re-
gardless of symptom, Holter and event monitors were only 
available for symptomatic recurrences; therefore, it is possi-
ble that some asymptomatic recurrences of atrial fibrillation 
were missed. The lack of significant differences in the long-
term follow-up is probably related to a too small number of 
patients in each group. Another factor that could explain the 
lack of differences is the longer duration of AF in the group 
treated by ablation.
In conclusion, hybrid therapy might be a reasonable ther-
apy for patients with anti-arrhythmic drug induced atrial 
flutter. The left atrial size was the strongest predictor of post-
ablation recurrence of atrial fibrillation. Careful patient se-
lection for hybrid therapy of atrial fibrillation may provide 
long term stable sinus rhythm. However, in patients with se-
vere atrial remodeling, rhythm control could not be main-
tained in prolonged period. Therefore, rate control without 
AAD might be a more reasonable approach for long term 
treatment in these patients.
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